ArticleCancer research communications2026
CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors.
Zhaopeng Sun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.